Omeprazole

Morbid Obesity

Fatih Sultan Mehmet Training and Research HospitalSmall moleculePhase 4 / ApprovedDormant

BB

70/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 58/ 100
Competitive Position: 89/ 100

Competitive context

61 Active assets in the Morbid Obesity cohort.

Asset / Sponsor	Phase	Rating
Lidocaine Instituto Mexicano del Seguro Social	Phase 4	BBB
Colesevelam Hvidovre University Hospital	Phase 4	BBB
Chenodeoxycholic Acid Hvidovre University Hospital	Phase 4	BBB
Ramifentanyl Hospital dos Lusíadas	Phase 4	BBB
Propofol G.Gennimatas General Hospital	Phase 4	BBB

View all 50 →

Same molecule, other indications

Omeprazole is also rated in:

primary mediastinal large B-cell lymphomaDormant

BB

Indicative · Phase 2

64 / 100

chemotherapy-induced neuropathyActive

BB

Indicative · Phase 3

64 / 100

relapsing-remitting multiple sclerosisDormant

B

Indicative · Phase 3

62 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.